Introduction
============

Tacrolimus is an effective immunosuppressant and its use is well established in solid organ transplantation.[@b1-dddt-12-295] Tacrolimus acts as an immunomodulatory agent by blocking the transcription of the gene encoding interleukin-2 (IL-2) that is essential for the T-cell-mediated immune response.[@b2-dddt-12-295],[@b3-dddt-12-295] As in other organ transplants, a variety of immunosuppressants have been used in combination in liver transplantation (LT). Among these immunosuppressive agents, tacrolimus is the most importantly used medication in LT.

Most countries have attempted to reduce the cost of transplant patient care, but the financial burdens of immunosuppressive therapy remain high.[@b4-dddt-12-295] Generally, generic drugs have a cost-saving effect. Minimizing drug costs is an important component in maintaining comprehensive and equitable health care.[@b4-dddt-12-295] For this reason, the development and use of generic tacrolimus is essential. Generic tacrolimus has met all the standards for demonstrating bioequivalence and is therapeutically equivalent to the reference tacrolimus, Prograf (PGF; Astellas Pharma Inc., Tokyo, Japan).[@b5-dddt-12-295] Tacrobell (TCB; Chong Kun Dang Pharmaceutical Corp, Seoul, Korea) is a generic formulation of tacrolimus that was approved in 2004 by the Korea Ministry of Food and Drug Safety.[@b6-dddt-12-295]

The purpose of this study was to evaluate the long-term efficacy and safety of generic tacrolimus, TCB, compared to PGF in liver transplant recipients. We retrospectively reviewed \~5 years of data concerning patients who were treated with TCB or PGF.

Patients and methods
====================

The present retrospective observational study was approved by the institutional review board of Catholic Medical Center, the Catholic University of Korea (approval no KC16RISI1029); the process of patient consent was waived because this study was a retrospective study of data from the medical records. Records that identified the subject of the study were kept confidential.

From January 2009 to March 2016, 499 adult patients underwent LT at our institution. Among them, 167 patients who used TCB or PGF for \>1 year were included in this retrospective analysis. This study was designed for patients who had been using TCB or PGF for \>1 year during a 7-year period (from January 2009 to March 2016), especially those who were followed up by a single surgeon for a more objective analysis. Of the 499 patients, 167 patients who underwent surgery and follow-up by one surgeon were selected to eliminate bias. TCB had been in use since January 2009, so our study period commenced from January 2009. The drugs used in the TCB and PGF groups were administered alternately for each patient, with no switch between TCB and PGF. There were no patients using TCB and PGF at the same time, and tacrolimus was discontinued and switched to mycophenolate mofetil (MMF) monotherapy or mechanistic target of rapamycin inhibitor. The TCB group included 86 patients and the PGF group included 81 patients. The mean follow-up duration was 53.0±25.52 months.

To determine the efficacy of TCB, we investigated the relationship between the drug dose and trough level of the drug, coefficient of variation (CV) values, mortality, survival, and rejection. CV values were obtained at the drug trough level for each patient to evaluate the intra-patient variability of tacrolimus and were compared between the two groups. CV was calculated according to the following equation: CV (%) = (σ/μ) ×100 (σ = standard deviation and μ = mean of the tacrolimus trough level). To investigate the safety of TCB, we reviewed the rate of rehospitalization, infection, kidney function (serum creatinine and glomerular filtration rate \[GFR\]), hypertension, metabolic disorder (diabetes and hypercholesterolemia), de novo malignancy, and drug side effects. We divided rejection into "biopsy proven" and "clinical" categories. Based on the Banff schema,[@b7-dddt-12-295] biopsy proven rejection defines mild rejection as 2\~3 points of the rejection activity index (RAI) and moderate rejection as ≥4 points. Patients who did not undergo biopsy but who had serum alanine aminotransferase (ALT) \>200 IU/L or total bilirubin \>3 mg/dL without biliary complication were defined as clinical suspicion of rejection. There were no exact criteria for biopsy. In patients with elevated liver enzyme, biopsy was performed if there was no improvement after conservative treatment. The same criteria were applied to both groups. Two groups of liver transplant patients were divided according to the chronic kidney disease (CKD) stages, and CKD stage 3 or higher (GFR \<60 mL/min/1.73 m^2^) was defined as renal dysfunction. No patient underwent simultaneous liver--kidney transplantation. Patients with hypertension (systolic \>140 mmHg or diastolic \>90 mmHg), diabetes (fasting blood sugar ≥126 mg/dL), and hypercholesterolemia (total cholesterol \>200 mg/dL or high density lipoprotein cholesterol \<40 mg/dL) were defined as having met the diagnostic criteria for the disease or were treated with medications.

Immunosuppressive treatment included a regimen featuring tacrolimus (TCB or PGF) as a component of a double- or triple-drug cocktail (the other two drugs were prednisone and MMF). The initial dose of tacrolimus was 1 mg and was adjusted daily by checking the trough levels. An IL-2 receptor blocker was administered on the day of the operation and on the fourth postoperative day. Steroids were withdrawn 1 month after surgery, and MMF was withdrawn 6 months after surgery. The immunosuppressive protocol did not differ between the two groups.

Statistical analysis
--------------------

Numerical data are presented as means with standard deviations. Continuous variables (means, standard deviations, medians, and ranges) were analyzed using the independent *t*-test or the chi-squared test, and proportions were compared using Pearson's chi-squared and Fisher's exact tests. Overall survival and rejection-free survival (RFS) rates were estimated using the Kaplan--Meier method and survival curves were compared with the aid of the log-rank test. All statistical analyses were performed using the SPSS software (version 19.0; IBM Corporation, Armonk, NY, USA). *p*-values \<0.05 were considered to indicate statistical significance.

Results
=======

Patient demographics
--------------------

A total of 167 patients who underwent LT up to March 2016 were reviewed. The TCB (n=86) and PGF (n=81) groups were compared according to their demographics and characteristics. During the observation period, 25 patients (29.1%) in the TCB group and 12 patients (14.8%) in the PGF group discontinued medication or switched to other drugs, and this difference was significant (*p*=0.027). The most common cause of drug change or interruption was nephrotoxicity in both groups; however, there was no significant difference between nine of these patients (10.5%) in the TCB group and five of these patients (6.2%) in the PGF group (*p*=0.391). There was no significant cause of drug change other than nephrotoxicity. We compared age, sex, body mass index, cause of liver disease, prevalence of hepatocellular carcinoma, Child--Pugh score, model for end-stage liver disease score, ratio of living donor living transplantation, preoperative creatinine, estimated GFR, CKD stage, ALT, total bilirubin, prevalence of preoperative diabetes, hypertension, and hypercholesterolemia, and mean follow-up duration. No differences were identified between the two groups ([Table 1](#t1-dddt-12-295){ref-type="table"}).

Efficacy
--------

The TCB group tended to use fewer drugs for the first week after transplantation, but thereafter there was no difference in drug dose between the two groups. The blood drug trough level was higher in the TCB group on the third postoperative day. Within 1 week, TCB tended to have higher drug trough levels even with low doses, but there was no difference between the two groups after this time ([Figure 1](#f1-dddt-12-295){ref-type="fig"}). CV values were then obtained at the drug trough level for each patient and were compared between the two groups. There were no differences in CV values within the course of 1 year (*p*=0.587) and up to 5 years (*p*=0.824) in both groups. There was also no difference between rejection and non-rejection when comparing CV values according to rejection ([Table 2](#t2-dddt-12-295){ref-type="table"}).

Biopsy proven rejection occurred in 15 patients (17.4%) in the TCB group and 29 patients (29.6%) in the PGF group, but this difference was not significant (*p*=0.063). However, a moderate RAI value of four or higher was more common in the PGF group (*p*=0.039), and the mean RAI was significantly higher in the PGF group compared to the TCB group (*p*=0.048). The clinical suspicion of rejection without biopsy (ALT \>200 U/L or total bilirubin 3 mg/dL, without biliary complication) was significantly higher in the TCB group (n=13, 15.1%) than in the PGF group (n=3, 3.7%) (*p*=0.012). However, there was no significant difference in terms of total rejection (biopsy proven rejection and clinically suspected rejection) between 28 patients (32.6%) in the TCB group and 27 patients (33.3%) in the PGF group (*p*=0.915). In the TCB group, eight patients (9.3%) underwent steroid pulse therapy for rejection and all of them responded to it. In the PGF group, 14 patients (17.3%) underwent steroid pulse therapy, but four patients did not respond; these four patients were treated with antithymocyte globulin ([Table 3](#t3-dddt-12-295){ref-type="table"}). We then compared RFS in the TCB and PGF groups according to the total rejection. No significant difference in RFS was detected between the TCB and PGF groups (*p*=0.837) ([Figure 2](#f2-dddt-12-295){ref-type="fig"}).

Safety
------

The rehospitalization rate of the TCB group was 58.1% and that of the PGF group was 70.4%, but this difference was not significant (*p*=0.1). The frequency of rehospitalization was subdivided into early rehospitalization (within 30 days) and late rehospitalization (after 30 days). Early rehospitalization and late rehospitalization of the TCB group were 24 (48.0%) and 26 (52.0%), respectively, and 26 (46.4%) and 30 (53.6%) for the PGF group which did not differ significantly (*p*=0.871). The most common cause of readmission in both groups was infection, followed by biliary complication and rejection.

During the postoperative follow-up period, no difference was found in the incidence of overall infection between the groups (48.8% in the TCB group vs 50.6% in the PGF group, *p*=0.818). However, the incidence of pneumonia was 5.8% (n=5) in the TCB group and 18.5% (n=16) in the PGF group and was significantly lower in the TCB group (*p*=0.011). There was no difference in the incidence of tuberculosis, wound infections, virus infection (herpes zoster and cytomegalovirus), fungal infections, and *Pneumocystis carinii* pneumonia ([Table 4](#t4-dddt-12-295){ref-type="table"}).

No difference was found in the mean GFR between preoperative and postoperative 5 years between each group. However, at 5 years postoperatively, the GFR in the TCB group was 69.2 mL/min/1.73 m^2^, which was higher than that in the PGF group (58.9 mL/min/1.73 m^2^, *p*=0.030) ([Figure 3](#f3-dddt-12-295){ref-type="fig"}). The frequency of CKD stage 3 or higher renal dysfunction was then examined. The incidence of patients aggravated beyond CKD stage 3 (GFR \<60 mL/min/1.73 m^2^) did not differ between the two groups over the entire follow-up period ([Table 5](#t5-dddt-12-295){ref-type="table"}).

To compare drug safety, objective signs (hypertension, diabetes, hypercholesterolemia, and de novo neoplasm) and subjective symptoms were compared between the groups. There was no difference in the incidence of newly developed hypertension (*p*=0.667), diabetes (*p*=0.353), and hypercholesterolemia (*p*=0.358) in the TCB and PGF groups, and there was also no difference in the incidence of de novo neoplasm (*p*=0.195) ([Table 6](#t6-dddt-12-295){ref-type="table"}). Drug side effects occurred in 59 patients (68.6%) in the TCB group and in 62 patients (76.5%) in the PGF group, but the difference was not significant (*p*=0.251). Itching (24.4%) was the most common adverse drug reaction in the TCB group, while skin rash (35.8%) was the most common adverse drug reaction in the PGF group ([Table 7](#t7-dddt-12-295){ref-type="table"}).

Discussion
==========

This study evaluated the long-term efficacy and safety of TCB, a generic tacrolimus, compared with PGF, the original form of tacrolimus, in patients undergoing adult LT followed up by a single surgeon. A major concern when administering general immunosuppressants is whether bioequivalence determined through single-dose studies in healthy adults is sufficient evidence of therapeutic equivalence in solid organ transplant patients.[@b4-dddt-12-295],[@b8-dddt-12-295] Yu et al[@b9-dddt-12-295] reported that TCB, as generic tacrolimus, can be considered safe and effective in liver transplant patients. However, they used an open-label, non-comparative study with a short-term follow-up. Because no previous studies had assessed the long-term efficacy and safety of TCB for LT patients, we analyzed our data to compare the long-term efficacy and safety of both TCB and PGF.

Within the first week, TCB tended to result in higher drug trough levels even with low doses. This finding appears to be similar to the results of previous pharmacokinetic studies of TCB in healthy subjects, who tended to have slightly higher drug trough concentrations after administration of TCB.[@b10-dddt-12-295] Further studies will be needed to confirm this result. However, we observed no difference in terms of drug dose and drug concentration between the two groups after the first week after surgery. High intra-patient variability of calcineurin inhibitors in the early posttransplantation stage has been related to worse outcomes in both adult and pediatric kidney and liver transplant recipients.[@b11-dddt-12-295]--[@b13-dddt-12-295] To evaluate the intra-patient variability of tacrolimus, we measured CV values in both groups. In our study population, the two groups did not differ in CV values within the first year (*p*=0.587) and up to 5 years (*p*=0.824). Although the severity of rejection was higher in the PGF group, there was no difference in total rejection between the two groups. There was also no difference in RFS between the groups. Biopsy was performed if there was no improvement after conservative treatment, so there may be some bias here. However, bias was minimized because the same criteria were applied to both groups. Together, our results demonstrated that the efficacy of TCB was not inferior to that of the original drug, PGF.

We subsequently evaluated the safety of TCB. During the follow-up period, there was no difference in the rehospitalization rate between the two groups (*p*=0.100). Additionally, the overall infection rate did not differ between the two groups (*p*=0.818). Although the incidence of pneumonia was higher in the PGF group, there was no difference in terms of other infections. Serum creatinine and GFR were compared between the two groups to observe changes in renal function. No difference in GFR was identified between the two groups during the follow-up period, but GFR at 5 years was higher in the TCB group than in the PGF group. Although not statistically significant, the TCB group showed relatively low incidence of renal dysfunction at the 5-year follow-up. However, because of nephrotoxicity, the TCB group is more likely to change or discontinue medication, which is not likely to be significant. This was thought to be due to nephrotoxicity-mediated drug withdrawal in nine patients in the TCB group and five patients in the PGF group. The incidence of new-onset hypertension, diabetes, hypercholesterolemia, and de novo neoplasm did not differ between the groups. Moreover, there was no difference between the two groups in terms of drug side effects. A previous study of kidney transplant patients also found no difference in adverse events (cardiovascular events, cerebrovascular events, malignancies, newly diagnosed onset of diabetes, and infectious events).[@b14-dddt-12-295] These results indicate that TCB is as safe as PGF.

The limitations of this study include the retrospective nature of the work. To assure physicians of the efficacy and safety of a generic immunosuppressant drug, the drug should be validated by prospective, multicenter, large-scale, double-blind, randomized, and long-term clinical trials.[@b15-dddt-12-295],[@b16-dddt-12-295] However, it is not easy to conduct such an ideal clinical trial with a generic drug. This study only targeted patients who were followed up by one surgeon, so the bias by the investigator was minimized. Therefore, the present study is meaningful because it provides a relatively long-term result, although the study itself is retrospective and the study population is small.

In conclusion, TCB, a generic drug, yielded results similar to those of PGF in various parameters for efficacy and safety. TCB is a comparable alternative to the original tacrolimus as a main immunosuppressive drug. Future prospective long-term, multicenter trials are required to support this conclusion.
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###### 

Comparison of the demographics and characteristics between the TCB and PGF groups

                                  TCB (n=86)         PGF (n=81)         *p*-value
  ------------------------------- ------------------ ------------------ -----------
  Age (years)                     51.64±8.76         51.94±8.25         0.821
  Male                            56 (65%)           58 (72%)           0.368
  Body mass index                 24.30±3.37         25.35±3.84         0.061
  HBV:HCV:alcoholic:others        47 (55%):6:19:14   51 (63%):3:17:10   0.616
  Hepatocellular carcinoma        29 (33.7%)         37 (45.7%)         0.114
  Child--Pugh score               9.14±2.83          9.23±2.92          0.831
  MELD score                      16.58±11.07        17.89±11.76        0.460
  LDLT                            73 (84.9%)         64 (79.0%)         0.323
  Creatinine, mg/dL               1.34±2.33          1.13±0.95          0.436
  eGFR (mL/min/1.73 m^2^)         94.19±45.75        92.61±39.67        0.812
  CKD stage (1:2:3:4:5)           48:22:8:5:3        47:13:17:2:2       0.141
  Alanine transferase (U/L)       189.38±594.42      231.68±865.05      0.712
  Total bilirubin (mg/dL)         7.61±11.4          9.35±13.36         0.365
  Blood pressure, mmHg            119.40±16.72       119.53±17.05       0.959
  Preoperative hypertension (%)   12 (14.0%)         12 (14.8%)         0.874
  Fasting blood sugar, mg/dL      117.56±49.19       125.27±44.11       0.289
  Preoperative diabetes (%)       17 (19.8%)         23 (28.4%)         0.192
  Mean cholesterol, mg/dL         130.26±48.02       116.37±46.60       0.096
  Hypercholesterolemia (%)        1 (1%)             0                  0.330
  Follow-up period (months)       51.45±24.25        54.68±26.85        0.416

**Note:** Data presented as mean ± SD unless otherwise indicated.

**Abbreviations:** HBV, hepatitis B virus; HCV, hepatitis C virus; LDLT, living donor liver transplantation; MELD, Model for End-Stage Liver Disease; eGFR, estimated glomerular filtration rate; PGF, Prograf; TCB, Tacrobell; CKD, chronic kidney disease.

###### 

Incidence of rehospitalization according to the two groups

                       TCB (n=86)   PGF (n=81)   *p*-value
  -------------------- ------------ ------------ -----------
  CV (within 1 year)   39.1±14.72   40.3±15.30   0.587
  CV (up to 5 years)   40.8±14.12   41.3±14.10   0.824

**Note:** Data presented as mean ± SD unless otherwise indicated.

**Abbreviations:** CV, coefficient of variation; PGF, Prograf; TCB, Tacrobell.

###### 

Comparison of rejection episodes in the TCB and PGF groups

                                  TCB (n=86)   PGF (n=81)   *p*-value
  ------------------------------- ------------ ------------ -----------
  Biopsy proven                   15 (17.4%)   24 (29.6%)   0.063
   Moderate rejection             7 (8.1%)     18 (22.2%)   0.039
   Mean RAI                       3.60±1.81    4.79±1.74    0.048
  Clinical rejection              13 (15.1%)   3 (3.7%)     0.012
  Rejection (biopsy + clinical)   28 (32.6%)   27 (33.3%)   0.915
  Steroid pulse therapy           8 (9.3%)     14 (17.3%)   0.127
  Steroid-resistant rejection     0            4 (4.9%)     0.037

**Note:** Moderate rejection: RAI ≥4.

**Abbreviations:** RAI, rejection activity index; PGF, Prograf; TCB, Tacrobell.

###### 

Comparison of infection rates in TCB and PGF groups

                            TCB (n=86)   PGF (n=81)   *p*-value
  ------------------------- ------------ ------------ -----------
  Overall infections        42 (48.8%)   41 (50.6%)   0.818
   Pneumonia                5 (5.8%)     15 (18.5%)   0.011
   Tuberculosis             1 (1.2%)     4 (4.9%)     0.152
   Wound infection          2 (2.3%)     1 (1.2%)     0.596
   Herpes zoster            13 (15.1%)   10 (12.3%)   0.604
   Cytomegalovirus          17 (19.8%)   19 (23.5%)   0.562
   Fungal infection         6 (7%)       10 (12.3%)   0.239
    *Aspergillus*           1 (17%)      6 (60%)      
    *Candida*               5 (83%)      4 (40%)      
   *Pneumocystis carinii*   2 (2.3%)     1 (1.2%)     0.596
   Pneumonia                                          
   Fever, unknown origin    9 (10.5%)    5 (6.2%)     0.317

**Abbreviations:** PGF, Prograf; TCB, Tacrobell.

###### 

Incidence of renal dysfunction (GFR \<60 mL/min/1.73 m^2^) in both groups

                  Preop   3rd Week   3rd Month   6th Month   1st Year   2nd Year   3rd Year   4th Year   5th Year
  --------------- ------- ---------- ----------- ----------- ---------- ---------- ---------- ---------- ----------
  Tacrobell (%)   19      16         23          30          37         45         43         45         33
  Prograf (%)     26      15         36          37          37         44         37         45         46
  *p*-value       0.26    0.79       0.08        0.35        0.94       0.95       0.54       0.98       0.3

**Abbreviations:** GFR, glomerular filtration rate; Preop, preoperative.

###### 

Incidence of new-onset hypertension, diabetes, hypercholesterolemia, and de novo neoplasm

                         TCB (n=86)   PGF (n=81)   *p*-value
  ---------------------- ------------ ------------ -----------
  Hypertension           26 (30.2%)   27 (33.3%)   0.667
  Diabetes               23 (26.7%)   27 (33.3%)   0.353
  Hypercholesterolemia   29 (33.7%)   22 (27.2%)   0.358
  De novo neoplasm       4 (4.7%)     1 (1.2%)     0.195

**Abbreviations:** PGF, Prograf; TCB, Tacrobell.

###### 

Drug side effects in the two groups

                         TCB (n=86)   PGF (n=81)   *p*-value
  ---------------------- ------------ ------------ -----------
  Overall side effects   59 (68.6%)   62 (76.5%)   0.251
   Headache              10 (11.6%)   10 (12.3%)   0.886
   Numbness              19 (22.1%)   22 (27.2%)   0.447
   Hair loss             13 (15.1%)   17 (21.0%)   0.323
   Itching               21 (24.4%)   21 (25.9%)   0.822
   Skin rash             20 (23.3%)   29 (35.8%)   0.075
   Diarrhea              11 (12.8%)   9 (11.1%)    0.738

**Abbreviations:** PGF, Prograf; TCB, Tacrobell.
